Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

70.98
BATS BZX Real-Time Price
As of 12:21pm ET
 -0.25 / -0.35%
Today’s Change
51.82
Today|||52-Week Range
73.06
+3.18%
Year-to-Date
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
12:04pm / Zacks.com - Paid Partner Content
AstraZeneca's Severe Asthma Drug Positive in Phase III
May 18 / Zacks.com - Paid Partner Content
PDL BioPharma Agrees to Equity Investment in Noden Pharma
10:41am / Zacks.com - Paid Partner Content
Bristol-Myers' Opdivo Wins FDA Nod for Additional Indication
May 18 / Zacks.com - Paid Partner Content
AbbVie/Boehringer Report Crohn's Disease Drug Interim Data
10:41am / Zacks.com - Paid Partner Content
Trevena (TRVN) Down on Negative Phase IIb Data on TRV027
May 17 / Zacks.com - Paid Partner Content
Biodel/Albireo Limited to Combine; Focus on Liver Diseases
10:17am / Zacks.com - Paid Partner Content
Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio
May 17 / Zacks.com - Paid Partner Content
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?
8:08am / MotleyFool.com - Paid Partner Content
Why a Mid-Stage Trial Is Causing Aduro Biotech to Tumble 22% Today
May 16 / MotleyFool.com - Paid Partner Content
Xenoport to be Acquired by Arbor Pharmaceuticals; Stock Up
May 24 / Zacks.com - Paid Partner Content
Pfizer (PFE) Reveals Positive Phase III Data on Trumenba
May 16 / Zacks.com - Paid Partner Content
Pfizer Champix's Label to Include More Data, Warning Lifted
May 24 / Zacks.com - Paid Partner Content
5 Surprising Comments in Merck's Quarterly Conference Call
May 13 / MotleyFool.com - Paid Partner Content
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May 24 / Zacks.com - Paid Partner Content
Kite Pharma (KITE) Upgraded to Hold on Strong Fundamentals
May 13 / Zacks.com - Paid Partner Content
Baron Funds Comments on Bristol-Myers Squibb
May 23 / GuruFocus News - Paid Partner Content
Bayer Stops Phase II Adempas Study Due to Safety Issues
May 13 / Zacks.com - Paid Partner Content
Pfizer's (PFE) Trumenba Accepted for Review in the EU
May 23 / Zacks.com - Paid Partner Content
Dr. Reddy's (RDY) Q4 Earnings & Revenues Decline Y/Y
May 13 / Zacks.com - Paid Partner Content
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
May 23 / Zacks.com - Paid Partner Content
Bristol-Myers/AbbVie Empliciti Gets Approved in the EU
May 12 / Zacks.com - Paid Partner Content
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
May 20 / Zacks.com - Paid Partner Content
Exelixis, Inc. Prepares for Blastoff
May 12 / MotleyFool.com - Paid Partner Content
Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down
May 20 / Zacks.com - Paid Partner Content
Why I Think Pfizer Is a Better Buy Than Merck & Co.
May 12 / MotleyFool.com - Paid Partner Content
Looking for a Top Momentum Stock? 3 Reasons Why Bristol-Myers (BMY) is a Great Choice
May 20 / Zacks.com - Paid Partner Content
AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
May 11 / Zacks.com - Paid Partner Content
Will These Game-Changing Cancer Treatments Hit the Market in 2016?
May 19 / MotleyFool.com - Paid Partner Content
Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger
May 11 / Zacks.com - Paid Partner Content
ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
May 19 / Zacks.com - Paid Partner Content
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
May 11 / Zacks.com - Paid Partner Content
Bristol-Myers Reports Two-Year Overall Survival Opdivo Data
May 19 / Zacks.com - Paid Partner Content
Pfizer to trial triple-combination cancer treatment
May 09 / FT.com - Paid Partner Content
Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
May 19 / Zacks.com - Paid Partner Content